Patents by Inventor Michael Colin Cramp
Michael Colin Cramp has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 8394830Abstract: Compounds of formula (I) are CRTH2 ligands, useful in the treatment of, for example, asthma and COPD wherein: R1 is halogen or cyano; R2 is hydrogen or methyl; R3 and R4 are independently —OR6, C1-C6alkyl or C3-C6cycloalkyl, the latter two groups being optionally substituted by one or more halogen atoms; R5 is hydrogen or halogen; R6 is C1C6alkyl or C3-C6cycloalkyl, either of which being optionally substituted by one or more halogen atoms; X is —CH2—, —S—, or —O—; one of Y and Y1 is hydrogen and the other is OR6, —C(?O)R7, NR8SO2R6 or a heterocyclic group selected from those referred to in the specification; and R6, R7 and R8 are as defined in the specification.Type: GrantFiled: March 30, 2012Date of Patent: March 12, 2013Assignee: Pulmagen Therapeutics (Asthma) LimitedInventors: John Gary Montana, Harry Finch, George Hynd, Michael Colin Cramp, Rosa Arienzo, Neville McLean
-
Publication number: 20120184579Abstract: Compounds of formula (I) are CRTH2 ligands, useful in the treatment of, for example, asthma and COPD wherein: R1 is halogen or cyano; R2 is hydrogen or methyl; R3 and R4 are independently —OR6, C1-C6alkyl or C3-C6cycloalkyl, the latter two groups being optionally substituted by one or more halogen atoms; R5 is hydrogen or halogen; R6 is C1C6alkyl or C3-C6cycloalkyl, either of which being optionally substituted by one or more halogen atoms; X is —CH2—, —S—, or —O—; one of Y and Y1 is hydrogen and the other is OR6, —C(?O)R7, NR8SO2R6 or a heterocyclic group selected from those referred to in the specification; and R6, R7 and R8 are as defined in the specification.Type: ApplicationFiled: March 30, 2012Publication date: July 19, 2012Inventors: John Gary Montana, Harry Finch, George Hynd, Michael Colin Cramp, Rosa Arienzo, Neville McLean
-
Patent number: 8173812Abstract: Compounds of formula (I) are CRTH2 ligands, useful in the treatment of, for example, asthma and COPD wherein: R1 is halogen or cyano; R2 is hydrogen or methyl; R3 and R4 are independently —OR6, C1-C6alkyl or C3-C6cycloalkyl, the latter two groups being optionally substituted by one or more halogen atoms; R5 is hydrogen or halogen; R6 is C1-C6 alkyl or C3-C6 cycloalkyl, either of which being optionally substituted by one or more halogen atoms; X is —CH2—, —S—, or —O—; one of Y and Y1 is hydrogen and the other is OR6, —C(?O)R7, NR8SO2R6 or a heterocyclic group selected from those referred to in the specification; and R6, R7 and R8 are as defined in the specification.Type: GrantFiled: April 3, 2008Date of Patent: May 8, 2012Assignee: Pulmagen Therapeutics (Asthma) LimitedInventors: John Gary Montana, Harry Finch, George Hynd, Michael Colin Cramp, Rosa Arienzo, Neville McLean
-
Patent number: 7858640Abstract: Compounds of formula [1] are CRTH2 antagonists, useful in the treatment of conditions having an inflammatory components; in which: R1-R9 are various substituents; A is —CHR10—, —C(O)—, —S(O)n—, —O—, or —NR10— wherein n is an integer from 0-1 and R10 is selected from various substituents; B is a direct bond or a divalent radical; R11 and R12 are selected from cvarious substituents; X is a carboxylic acid, tetrazole, 3-hydroxyisoxazole, hydroxamic acid, phosphinate, phosphonate, phosphonamide, sulfonic acid group, or a group of formula C?(O)NHSO2R6 or SO2NHC(?O)R6; and Y is aryl, heteroaryl, aryl-fused-heterocycloalkyl, heteroaryl-fused-cycloalkyl, heteroaryl-fused-heterocycloalkyl or aryl-fused-cycloalkyl group.Type: GrantFiled: September 29, 2006Date of Patent: December 28, 2010Assignee: Pulmagen Therapeutics (Asthma) LimitedInventors: Michael Colin Cramp, Rosa Arienzo, George Hynd, Peter Crackett, Yann Griffon, Trevor Keith Harrison, Nicholas Charles Ray, Harry Finch, John Gary Montana
-
Publication number: 20100144786Abstract: Specific quinoline derivatives are CRTH2 antagonists, useful in the treatment of conditions having an inflammatory component.Type: ApplicationFiled: March 29, 2007Publication date: June 10, 2010Inventors: Michael Colin Cramp, Rosa Arienzo, George Hynd, Peter Crackett, Yann Griffon, Trevor Keith Harrison, Nicholas Charles Ray, Harry Finch, John Gary Montana
-
Publication number: 20100144787Abstract: Compounds of formula (I) are CRTH2 ligands, useful in the treatment of, for example, asthma and COPD wherein: R1 is halogen or cyano; R2 is hydrogen or methyl; R3 and R4 are independently —OR6, C1-C6alkyl or C3-C6cycloalkyl, the latter two groups being optionally substituted by one or more halogen atoms; R5 is hydrogen or halogen; R6 is C1C6 alkyl or C3-C6 cycloalkyl, either of which being optionally substituted by one or more halogen atoms; X is —CH2—, —S—, or —O—; one of Y and Y1 is hydrogen and the other is OR6, —C(?O)R7, NR8SO2R6 or a heterocyclic group selected from those referred to in the specification; and R6, R7 and R8 are as defined in the specification.Type: ApplicationFiled: April 3, 2008Publication date: June 10, 2010Inventors: John Gary Montana, Harry Finch, George Hynd, Michael Colin Cramp, Rosa Arienzo, Neville McLean
-
Publication number: 20100137300Abstract: The specific compounds of this list: {7-cyano-2-methyl-1-[4-(morpholine-4-sutfonyl)benzyl]indolizin-3-yl}acetic acid, {1-(3-chloro-4-ethanesulfonylbenzyl)-7-cyano-2-methylindolizin-3-yl}acetic acid, {1-[3-chloro4-(morpholine-4-sulfonyl)benzyl]-7-cyano-2-methylindolizin-3-yl}acetic acid, {1-(3-chloro-4-ethanesulfonylphenylsulfanyl)-7-cyano-2-methylindolizin-3-yl}acetic acid, {1-[3-chloro-4-(morpholine-4-sutfonyl)phenylsutfanyl]-7-cyano-2-methylindolizin-3-yl}acetic acid, {7-cyano-1-(6-fluoroquinolin-2-ylmethyl)-2-methylindolizin-3-yl}acetic acid are ligands of the CRTH2 receptor and are useful in the treatment of respiratory diseases.Type: ApplicationFiled: March 21, 2007Publication date: June 3, 2010Inventors: George Hynd, Nicholas Charles Ray, Harry Finch, John Gary Montana, Michael Colin Cramp, Trevor Keith Harrison, Rosa Arienzo, Paul Blaney, Yann Griffon, David Middlemiss
-
Publication number: 20100010034Abstract: The following compounds are CRTH2 antagonists, useful in treatment of respiratory disease: [3-(2,4-dichlorophenylsulfanyl)-6-fluoro-2-methylindolizin-1-yl]acetic acid, [6-fluoro-3-(2-fluoro-4-methanesulfonylphenylsulfanyl)-2-methylindolizin-1-yl]acetic acid, [6-fluoro-3-(4-methanesulfonyl-2-trifluoromethylphenylsulfanyl)-2-methylindolizin-1-yl]acetic acid, (R)-2-[6-fluoro-3-(4-methanesulfonylphenylsulfanyl)-2-methylindolizin-1-yl]propionic acid, [3-(4-ethanesulfonylphenylsulfanyl)-6-fluoro-2-methylindolizin-1-yl]acetic acid, (S)-2-[6-fluoro-3-(4-methanesulfonylphenylsulfanyl)-2-methylindolizin-1-yl]propionic acid, ethanesulfonylaminobenzenesulfonyl)-6-fluoro-2-methyiindolizin-1-yl]acetic acid, [7-chloro-6-fluoro-3-(4-methanesulfonylphenylsulfanyl)-2-methylindolizin-1-yl]acetic acid, [3-(2-chloro-4-methanesulfonylphenylsulfanyl)-7-cyano-2-methylindolizin-1-yl]acetic acid, [6-cyano-3-(4-methanesulfonylbenzyl)-2-methylindolizin-1-yl]acetic acid, [3-(4-chlorobenzyl)-7-cyano-2-methylindolizin-1-yl]acetic acid, [6-Type: ApplicationFiled: December 21, 2006Publication date: January 14, 2010Inventors: George Hynd, Nicholas Charles Ray, Harry Finch, David Middlemiss, Michael Colin Cramp, Paul Matthew Blaney, Karen Williams, Yann Griffon, Trevor Keith Harrison, Peter Crackett
-
Publication number: 20090163534Abstract: Compounds of formula (I) are ligands of the CRTH2 receptor and are useful in the treatment of respiratory disease: Formula (I) wherein R1, R2, R3 and R4 each independently are hydrogen, C1C6alkyl, fully or partially fluorinated C1C6alkyl, halo, —S(O)nR10, —SO2N(R10)2, —N(R10)2, —C(O)N(R10)2, —NR10C(O)R9, —CO2R10, —C(O)R9, —NO2, —CN or —OR11; wherein each R9 is independently C1C6alkyl, aryl, heteroaryl; R10 is independently hydrogen, C1C6alkyl, aryl, or heteroaryl; R11 is hydrogen, C1C6alkyl, fully or partially fluorinated C1C6alkyl or a group —SO2R9; n is 0, 1 or 2; R5 is C1C6alkyl, fully or partially fluorinated C1C6alkyl. C1C6alkenyl, C1C6alkynyl, optionally substituted aryl, or optionally substituted heteroaryl; R6 is hydrogen, C1C6alkyl or fully or partially fluorinated C1C6alkyl; R7 and R5 are independently hydrogen or C1C6alkyl, or R7 and R5 together with the atom to which they are attached form a cycloalkyl group; and X is —CHR6—, —S(O)n—, —NR6SO2— or —SO2NR6— wherein n is 0, 1 or 2.Type: ApplicationFiled: June 26, 2006Publication date: June 25, 2009Inventors: George Hynd, Nicholas Charles Ray, Harry Finch, David Middlemiss, Michael Colin Cramp, Paul Matthew Blaney, Karen Williams, Yan Griffon, Trevor Keith Harrison, Peter Crackett
-
Publication number: 20090156600Abstract: Compounds of formula [1] are CRTH2 antagonists, useful in the treatment of conditions having an inflammatory component; in which: R1, R2, R3, R4 and R5 are independently hydrogen, C1-C6alkyl, C1-C6-fluoroalkyl, cyclopropyl, halo, —S(O)nR6, —SO2NR7R8, —NR7R8, —NR7C(O)R6, —CO2R7, —C(O)NR7R8, —C(O)R76, —NO2, —CN or a group —OR9; wherein each R6 is independently C1-C6alkyl, C1-C6-fluoroalkyl, cycloalkyl, aryl, or heteroaryl; R7, R8 are independently C1-C6alkyl, C1-C6-fluoroalkyl, cycloalkyl, cycloalkyl-(C1-C6alkyl)-, aryl, heteroaryl or hydrogen; R9 is hydrogen, C1-C6alkyl, C1-C6-fluoroalkyl, cycloalkyl, cylcoalkyl-(C1-C6alkyl)-, or a group —SO2R6; A is —CHR10—, —C(O)—, —S(O)n—, —O—, or —NR10— wherein n is an integer from 0-2 and R10 is hydrogen C1-C3alkyl, or C1-C6-fluoroalkyl group; B is a direct bond, or a divalent radical selected from —CH2—, —CH2CH2—, —CHR11—, —CR11R12—, —CH2CHR11—, CH2CR11R12—, —CHR11CHR12—, and divalent radicals of formula —(CR11R12)p-Z- wherein Z is attached to the ring carrying R1, R2 anType: ApplicationFiled: September 29, 2006Publication date: June 18, 2009Inventors: Michael Colin Cramp, Rosa Arienzo, George Hynd, Peter Crackett, Yann Griffon, Trevor Keith Harrison, Nicholas Charles Ray, Harry Finch, John Gary Montana
-
Publication number: 20080306109Abstract: Compounds of formula (I) are CRTH2 antagonists, useful in the treatment of, for example, asthma, chronic obstructive pulmonary disease, rhinitis, allergic airway syndrome, and allergic rhinobronchitis. Formula (I) wherein R1, R2.Type: ApplicationFiled: September 14, 2006Publication date: December 11, 2008Inventors: George Hynd, Nicholas Charles Ray, Harry Finch, John Gary Montana, Michael Colin Cramp, Trevor Keith Harrison, Rosa Arienzo, Paul Blaney, Yann Griffon, David Middlemiss
-
Publication number: 20030181334Abstract: The invention relates to a method for the control of weeds (i.e.Type: ApplicationFiled: December 11, 2002Publication date: September 25, 2003Inventors: Clive Cornell, Michael Colin Cramp, Michael Gingell, Susan Westaway
-
Publication number: 20010029239Abstract: The invention relates to aryl vinyl ether compounds of formula (I): 1Type: ApplicationFiled: December 20, 2000Publication date: October 11, 2001Inventors: Michael Colin Cramp, Stephen Robert Mack, Michael Gingell
-
Patent number: 6046135Abstract: 1,3-Oxazin-4-one derivatives of formula (I): ##STR1## wherein Q represents --C(.dbd.O)--, --CH(OH)-- or --C(OR.sup.11)(OR.sup.11)--, in which R.sup.11 represents lower alkyl; or the two groups --OR.sup.11, together with the carbon atom to which they are attached, form a five or six membered cyclic ketal group; and their use as herbicides.Type: GrantFiled: September 2, 1998Date of Patent: April 4, 2000Assignees: Rhone-Poulenc Agriculture Ltd, Mitsubishi Chemical CorporationInventors: Michael Colin Cramp, Yoshihiro Usui, Sachio Kudo
-
Patent number: 6028032Abstract: 1,3-oxazin-4-ones of formula (I), ##STR1## wherein R.sup.1 represents phenyl optionally substituted; R.sup.2 represents: a straight- or branched-chain alkyl having from one to ten carbon atoms which is substituted by one or more groups R.sup.8 which may be the same or different; a straight- or branched-chain optionally halogenated alkenyl or alkynyl group having up to ten carbon atoms; or a group selected from cyano, --CHO, --COR.sup.7, --CO.sub.2 H, --CO.sub.2 R.sup.7, --COSR.sup.7, --CONR.sup.9 R.sup.10, --CH.dbd.NOH, --CH.dbd.NOR.sup.7, --CH.dbd.NOCOR.sup.7, --CH.dbd.NNR.sup.9 R.sup.10, --CH.sub.2 CN, --CH.sub.2 NO.sub.2 and oxiranyl; R.sup.3 represents phenyl optionally substituted or R.sup.3 represents a first five to seven membered heteroaromatic ring; said first ring being optionally fused and said first ring being linked to the nitrogen atom of the group NR.sup.6 via one of the ring carbon atoms; R.sup.4 and R.sup.5 independently represent lower alkyl; W represents --NR.sup.6 --; R.sup.Type: GrantFiled: April 13, 1998Date of Patent: February 22, 2000Assignee: Rhone-Poulenc Agriculture Ltd.Inventors: Michael Colin Cramp, Yoshihiro Usui, Keiichi Hayashizaki